Issue 32 | 2018
Get instant access to latest e-book

latest newsRead more...

15

Oct 2018

The Menarini Group Announces Commercial Agreement for Vabomere, Orbactiv and Minocin in 68 Countries

The Menarini Group an Italian biopharmaceutical company present in countries worldwide and Melinta Therapeutics a US company dedicated to the discovery development and commercialization of novel antibiotics to treat serious bacterial infections have announced an agreement under which Menarini will acquire the exclusive rights to…

15

Oct 2018

Telix and ANMI Expand PSMA Imaging Partnership

Telix Pharmaceuticals Limited a clinicalstage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularlytargeted radiation MTR today announced that it has expanded its partnership with Advanced Nuclear Medicine Ingredients SA ANMI for the GaHBEDCCPSMA GaPSMA cold kit…

12

Oct 2018

Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen

BristolMyers Squibb Company and Compugen today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugens COM an investigational antiPVRIG antibody in combination with BristolMyers Squibbs programmed death PD immune checkpoint inhibitor Opdivo nivolumab in patients with…

12

Oct 2018

Mundipharma Strengthens Position as a Leader in Biosimilars with Acquisition of Development Company Cinfa Biotech

The Mundipharma global network of independent associated companies has today added development capabilities to its biosimilars platform with the purchase of biosimilars development company Cinfa Biotech The announcement sees the Mundipharma network including NAPP Pharmaceuticals in the UK gain immediate access to Pelmeg B a…

11

Oct 2018

ROSLINCT and REPROCELL Awarded £1.2 Million from Innovate UK for Clinical-Grade Stem Cell Production

ROSLINCT a leading cell and gene therapy contract manufacturing organisation today announced it is to receive a million investment to collaborate with REPROCELL Europe Ltd REPROCELL a UKbased stem cell company on a project which will develop a faster more costeffective method of producing clinicalgrade…

press releasesRead more...

15

Oct 2018

MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD

MaaT Pharma announced today the dosing of the first patient in a Phase clinical trial of its lead microbiome restoration candidate MaaT in patients with steroidresistant acute GraftversusHostDisease SRaGvHD the…

12

Oct 2018

Synspira Receives U.S. FDA Orphan Designation for PAAG15A for the Treatment of Cystic Fibrosis

Synspira a privately held company developing a new class of inhaled glycopolymerbased therapeutics for the treatment of pulmonary disease today announced that it has been granted Orphan Designation by the…

12

Oct 2018

ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease

ProMIS Neurosciences Inc a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases today announced the identification of…

11

Oct 2018

Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc a leader in developing safer therapeutics for pain and inflammation is pleased to announce that it has received approval from Health Canada to initiate the first part…

11

Oct 2018

AUM LifeTech, CHOP and Penn Partnering to Advance Cancer Immunotherapy Against Lung Cancer Using Foxp3 Gene Silencing FANA ASO Therapy

AUM LifeTech Inc a Philadelphiabased biotech company has partnered with the Childrens Hospital of Philadelphia CHOP and the Perelman School of Medicine at the University of Pennsylvania to employ nextgeneration…

EventsRead more...

15-17

Oct 2018

IFAT India 2018

Messe Muenchen India Pvt. Ltd.
Bombay Exhibition Centre

15-17

Oct 2018

7th European TMF Summit

ExL Events, Inc.
Hilton London Bankside

16-18

Oct 2018

16-17

Oct 2018

15th Annual Patient Summit Europe

Eyeforpharma
Novotel London West Hotel

TOP ARTICLES

  • 2

    Are you Ready for EU FMD?

    With the deadline looming for enactment of EU FMD and US DSCSA Vikash Pushpraj Senior Vice President rfxcel explains how achieving compliance is about much more..
  • 4

    Cancer Stem Cell (CSC) Inhibitors

    Cancer as a group of heterogeneous diseases very well known Unimaginable amounts of money and manhours have been spent in finding cure for this deadly disease H..

Knowledge Bank

  • Interviews

    Merck

    Staff Engineer, Manufacturing Science and Technology, South East Asia
    Karen Chan is a process engineer at Merck Pte Ltd Chan has six years of experience in the biopharmaceutical industry and two years of experience in research development She provides technical support in areas such as process development troubleshoot..

  • Techno Trends

    Alnylam’s ONPATTRO to Treat Patients with Hereditary ATTR Amyloidosis in Adults

    Alnylams ONPATTRO patisiran lipid complex injection is a firstofitskind RNA interference RNAi therapeutic used to treat the polyneuropathy of hereditary transthyretinmediated hATTR Amyloidosis in adults RNAi is a completely new approach to the treatment of these diseases targeting the faulty protein that is causing the disease rather than treating the symptoms RNAi therapeutic is an entirely new class of medicines…

Editorial Section

  • Strategy

    Statin Drug Interactions and Related Adverse Reactions

    Statins are generally well tolerated with a low frequency of adverse events but since statins are prescribed on a longterm basis many patients will typically receive pharmacological therapy for concomitant conditions during the course of statin treatment and potentially interacting…

  • Research development

    Stem Cell and Gene Delivery

    These days gene and stem cell therapies have the potential to make the substantial impact on the treatment of several diseases However there are pros and cons of each strategy but the optimal selection of gene delivery vector or stem…

  • Clinical Trials

    Managing Clinical Trial Agreements

    Clinical Trial Agreements set out how a clinical trial will be run at the site and are an essential GCP document There are a number of key factors that determine whether a Clinical Trial Agreement is successful in achieving that…

  • Information Technology

    R&D DATA HUB

    Faster decision making and better trial oversight at all levels requires truly next generation data integration and analytics Source and format agnostic data aggregation aided by modern data lake architecture and advanced analytics deliver interactive…

TOP